Kimberly A Kilfoyle1, Lisa Rahangdale1, Stacie B Dusetzina2,3,4,5. 1. 1 Division of Women's Primary Heath Care, Department of Obstetrics & Gynecology, University of North Carolina School of Medicine , Chapel Hill, North Carolina. 2. 2 Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina. 3. 3 Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina. 4. 4 UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina. 5. 5 Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina.
Abstract
BACKGROUND: Young adult women find it acceptable to be offered the human papillomavirus (HPV) vaccine postpartum. Little is known about the practice of administering the HPV vaccine during the postpartum period. MATERIALS AND METHODS: The Truven Health Analytics MarketScan Commercial Claims and Encounters database was used to develop a cohort of privately insured 18 to 26-year-old women with uncomplicated live-born pregnancies. Eligibility required no previous doses of HPV vaccine before delivery and continuous insurance enrollment from June 2006 through 1 year postpartum. Descriptive statistics were performed. RESULTS: A total of 51,913 women meet age and enrollment criteria, with 3912 (7.5%) having received any doses of vaccine before their delivery, leaving 48,001 women in this cohort. In the year postpartum, 861 women (1.8%) received any HPV vaccine. Of the women initiating the vaccine, only 337 (39%) completed the three-vaccine series. Women who received the vaccine, compared with women who did not, were younger (21 vs. 23 years old), more often the dependent to the insurance beneficiary (56% vs. 30%), and were more likely to have had an abnormal pap smear in the year prior (19.6% vs. 9.1%) or postdelivery (16.4% vs. 4.9). More women completed the HPV vaccine series when initiated within 2 months postpartum compared with women initiating the vaccine series >2 months postpartum (44% vs. 38%). CONCLUSIONS: Postpartum women are eligible for the HPV vaccine, yet very few are receiving it. The postpartum period is a missed opportunity for administration of this cancer-preventing vaccine.
BACKGROUND: Young adult women find it acceptable to be offered the human papillomavirus (HPV) vaccine postpartum. Little is known about the practice of administering the HPV vaccine during the postpartum period. MATERIALS AND METHODS: The Truven Health Analytics MarketScan Commercial Claims and Encounters database was used to develop a cohort of privately insured 18 to 26-year-old women with uncomplicated live-born pregnancies. Eligibility required no previous doses of HPV vaccine before delivery and continuous insurance enrollment from June 2006 through 1 year postpartum. Descriptive statistics were performed. RESULTS: A total of 51,913 women meet age and enrollment criteria, with 3912 (7.5%) having received any doses of vaccine before their delivery, leaving 48,001 women in this cohort. In the year postpartum, 861 women (1.8%) received any HPV vaccine. Of the women initiating the vaccine, only 337 (39%) completed the three-vaccine series. Women who received the vaccine, compared with women who did not, were younger (21 vs. 23 years old), more often the dependent to the insurance beneficiary (56% vs. 30%), and were more likely to have had an abnormal pap smear in the year prior (19.6% vs. 9.1%) or postdelivery (16.4% vs. 4.9). More women completed the HPV vaccine series when initiated within 2 months postpartum compared with women initiating the vaccine series >2 months postpartum (44% vs. 38%). CONCLUSIONS: Postpartum women are eligible for the HPV vaccine, yet very few are receiving it. The postpartum period is a missed opportunity for administration of this cancer-preventing vaccine.
Authors: Jason D Wright; Shravya Govindappagari; Neha Pawar; Kirsten Cleary; William M Burke; Patricia C Devine; Yu-Shiang Lu; Wei-Yann Tsai; Sharyn N Lewin; Thomas J Herzog Journal: Obstet Gynecol Date: 2012-10 Impact factor: 7.661
Authors: Abbey B Berenson; Mahbubur Rahman; Jacqueline M Hirth; Richard E Rupp; Kwabena O Sarpong Journal: Am J Obstet Gynecol Date: 2016-02-17 Impact factor: 8.661
Authors: Gregory D Zimet; Nathan W Stupiansky; Thomas W Weiss; Susan L Rosenthal; Margaret B Good; Michelle D Vichnin Journal: Vaccine Date: 2010-11-25 Impact factor: 3.641
Authors: F Xavier Bosch; Ann N Burchell; Mark Schiffman; Anna R Giuliano; Silvia de Sanjose; Laia Bruni; Guillermo Tortolero-Luna; Susanne Kruger Kjaer; Nubia Muñoz Journal: Vaccine Date: 2008-08-19 Impact factor: 3.641
Authors: Walter W Williams; Peng-Jun Lu; Alissa O'Halloran; Carolyn B Bridges; David K Kim; Tamara Pilishvili; Craig M Hales; Lauri E Markowitz Journal: MMWR Morb Mortal Wkly Rep Date: 2015-02-06 Impact factor: 17.586
Authors: Sarah Reagan-Steiner; David Yankey; Jenny Jeyarajah; Laurie D Elam-Evans; James A Singleton; C Robinette Curtis; Jessica MacNeil; Lauri E Markowitz; Shannon Stokley Journal: MMWR Morb Mortal Wkly Rep Date: 2015-07-31 Impact factor: 17.586
Authors: Carlos R Oliveira; Robert M Rock; Eugene D Shapiro; Xiao Xu; Lisbet Lundsberg; Liye B Zhang; Aileen Gariepy; Jessica L Illuzzi; Sangini S Sheth Journal: Am J Obstet Gynecol Date: 2017-12-06 Impact factor: 10.693
Authors: Paige W Lake; Katharine J Head; Shannon M Christy; Andrea L DeMaria; Erika L Thompson; Susan T Vadaparampil; Gregory D Zimet; Monica L Kasting Journal: Prev Med Rep Date: 2022-04-20